{
    "organizations": [],
    "uuid": "e392e3a5387ba49b15359e38c1936bcc3f518fbf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-avenue-therapeutics-reports-positi/brief-avenue-therapeutics-reports-positive-topline-phase-3-data-for-intravenous-tramadol-in-the-management-of-postoperative-pain-idUSFWN1SS0GP",
    "ord_in_thread": 0,
    "title": "BRIEF-Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 21 (Reuters) - Avenue Therapeutics Inc:\n* AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN\n* AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE\n* AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE\n* AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018\n* AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL\n* AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS\n* AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-21T18:43:00.000+03:00",
    "crawled": "2018-05-22T19:17:25.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "avenue",
        "therapeutic",
        "inc",
        "avenue",
        "therapeutic",
        "announces",
        "positive",
        "topline",
        "phase",
        "data",
        "intravenous",
        "tramadol",
        "management",
        "postoperative",
        "pain",
        "avenue",
        "therapeutic",
        "inc",
        "iv",
        "tramadol",
        "achieved",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "well",
        "clear",
        "dose",
        "response",
        "avenue",
        "therapeutic",
        "inc",
        "iv",
        "tramadol",
        "achieved",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "well",
        "clear",
        "dose",
        "response",
        "avenue",
        "therapeutic",
        "inc",
        "initiation",
        "second",
        "pivotal",
        "phase",
        "trial",
        "planned",
        "q3",
        "avenue",
        "therapeutic",
        "inc",
        "iv",
        "tramadol",
        "report",
        "serious",
        "adverse",
        "event",
        "trial",
        "avenue",
        "therapeutic",
        "inc",
        "iv",
        "tramadol",
        "mg",
        "treatment",
        "arm",
        "generally",
        "displayed",
        "intermediate",
        "result",
        "fell",
        "mg",
        "placebo",
        "arm",
        "avenue",
        "therapeutic",
        "anticipate",
        "filing",
        "nda",
        "iv",
        "tramadol",
        "fda",
        "late",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}